Barr Ellison Solicitors – commercial property
Advertisement: Bridge Fibre mid
Advertisement Cambridge China Centre
Advertisement: Mobas mid banner
RealVNC mid-banner general
Advertisement: Cambridge Network
ARM Innovation Hub
Advertisement: Lynch Wood Park
Advertisement: RSM
Advertisement: EY
RealVNC mid banner careers
Advertisement: Bradfield Centre mid
11 December, 2018 - 23:59 By Tony Quested

Sosei Heptares makes its Cambridge bow

Japanese biopharma giant Sosei has reinforced its long-term commitment to Cambridge by rebranding its main operating business as Sosei Heptares in Tokyo and the UK.

The relaunch marks a new chapter for the company following the acquisition of Welwyn-based Heptares Therapeutics in February 2015 and the subsequent decision to move the UK bio hub to Granta Park.

The decision to combine the names of Sosei and Heptares is designed to retain the strong brand identities of both companies in domestic and international markets – particularly in Japan and the UK where the companies originate.

Sosei says the Heptares acquisition was transformational, enabling the new group to leverage the world leadership that Heptares had established in GPCR-focused structure-based drug design (SBDD) with experienced commercial management at Sosei to create an international biopharmaceutical group advancing a broad and deep pipeline of partnered and in-house drug candidates in multiple therapeutic areas. 

Since then, the company has enhanced its technology platform, advanced candidates through its pipeline into clinical development, added significant new partnership deals and collaborations and created a new GPCR-SBDD research centre of excellence in Cambridge, which was formally opened in October.

Shinichi Tamura, executive chairman and founder of Sosei, said: “In re-launching the company as Sosei Heptares, we are reflecting the great cooperation since 2015 of two teams with complementary expertise.

“Our decision to adopt a new global brand that combines the best of both names and identities represents a synergistic fusion of our Japanese-Anglo heritage. 

“It also signifies our intent to work together as one integrated company with a single purpose towards achieving our mission – to make a significant contribution to improving the quality of life and health of people around the world by applying our world-leading technology to discover, design and develop innovative and effective medicines for patients worldwide.”

• PHOTOGRAPH SHOWS: Mr. Shinichi Tamura. Image courtesy – Sosei Heptares

Newsletter Subscription

Stay informed of the latest news and features